Programs	Combination	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Milestone
Breast Cancer
BRACELET-1		HR+/HER2-mBC	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	ORR, PFS, evolving OS H1 '23
AWARE-1		HR+/HER2-BC	Window of Opportunity Study Preclinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started	Final Data Q4 '22
IRENE	Retifanlimab*	(TNBC)	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	Phase 2 Safety Data Q4 '21
Gastro-Intestinal Cancer
GOBLET		1L Adv/Metastatic Pancreatic Cancer	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	Interim Data Q4 '22
GOBLET		1L# mCRC	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	-
GOBLET		3L mCRC	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	Safety run-in Complete
GOBLET		2L Unresectable Anal Cancer	Preclinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started	-

*Anti-PD-1 checkpoint inhibitor in development by Incyte (also known as INCMGA00012); mBC: Metastatic Breast Cancer; BC: Breast Cancer; ORR: Overall Response Rate; PFS: Progression-Free Survival, OS: Overall Survival; TNBC: Triple-Negative Breast Cancer; Adv: Advanced; L: Line; 1L#: First-line MSI-high focused; mCRC: Metastatic Colorectal Cancer